The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Open accessAbstract
Survivin is the smallest member of the inhibitor of apoptosis protein family, which has key roles in regulating cell division and inhibiting apoptosis by blocking caspase activation. Survivin is highly expressed in most human cancers, such as lung, pancreatic and breast cancers, relative to normal tissues. Aberrant survivin expression is associated with tumor cell proliferation, progression, angiogenesis, therapeutic resistance, and poor prognosis. Studies on the underlying molecular mechanisms indicate that survivin is involved in the regulation of cytokinesis and cell cycle progression, as well as participates in a variety of signaling pathways such as the p53, Wnt, hypoxia, transforming growth factor, and Notch signaling pathways. In this review, recent progress in understanding the molecular basis of survivin is discussed. Therapeutic strategies targeting survivin in preclinical studies are also briefly summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Wahdan-Alaswad, R. S., Song, K. W., Krebs, T. L., Shola, D. T. N., Gómez, J. A., Matsuyama, S., & Danielpour, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1119 · Cited by 26
RetractedChen, W., Zhong, X. Y., Wei, Y., Liu, Y., Quan, Y., Zhang, G., He, L., Chen, F., Liu, Y., & Luo, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9121-6 · Cited by 21
RetractedChen, W., Zhong, X. Y., Wei, Y., Liu, Y., Quan, Y., Zhang, G., He, L., Chen, F., Liu, Y., & Luo, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0581-8 · Cited by 4
RetractedApoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528 · cited 1×
“During tumorigenesis, accumulation of β-catenin in the cytoplasm is recognized as the hallmark of the Wnt signaling pathway [77].”
BackgroundPI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,244
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis
Brentnall, M., Rodriguez-Menocal, L., De Guevara, R. L., Cepero, E., & Boise, L. H. (2013) · BMC Cell Biology · doi:10.1186/1471-2121-14-32 · Cited by 1,147
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Apoptosis, autophagy, necroptosis, and cancer metastasis
Su, Z., Yang, Z., Xu, Y., Chen, Y., & Yu, Q. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0321-5 · Cited by 1,042
The inhibitors of apoptosis (IAPs) and their emerging role in cancer
LaCasse, E. C., Baird, S., Korneluk, R. G., & MacKenzie, A. E. (1998) · Oncogene · doi:10.1038/sj.onc.1202569 · Cited by 982
Cytochrome c release from mitochondria proceeds by a two-step process
Ott, M., Robertson, J. D., Gogvadze, V., Zhivotovsky, B., & Orrenius, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241655498 · Cited by 954
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0746 · Cited by 765
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Ziello, J. E., Jovin, I. S., & Huang, Y. (2007) · PubMed Central · Cited by 655
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
Stewart, D. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt356 · Cited by 651
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A. P., et al. (2000) · PubMed · Cited by 620
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Mirza, A., McGuirk, M., Hockenberry, T. N., Wu, Q., Ashar, H., Black, S., Wen, S. F., Wang, L., Kirschmeier, P., Bishop, W. R., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205353 · Cited by 530
STAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
Song, Z., Yao, X., & Wu, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300957200 · Cited by 363
Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think
Lobry, C., Oh, P., & Aifantis, I. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111855 · Cited by 356
Allenspach, E. J., Maillard, I., Aster, J. C., & Pear, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.159 · Cited by 344
Signal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
A p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control
Zhang, C. (2014) · Protein & Cell · doi:10.1007/s13238-014-0083-7 · Cited by 297
Self-citationThe ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner
Zhao, J., Tenev, T., Martins, L. M., Downward, J., & Lemoine, N. R. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.23.4363 · Cited by 277
Schmidt, S. M., Schag, K., Müller, M. R., Weck, M. M., Appel, S., Kanz, L., Grünebach, F., & Brossart, P. (2003) · Blood · doi:10.1182/blood-2002-08-2554 · Cited by 277
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 231
Targeting survivin in cancer therapy: fulfilled promises and open questions
Pennati, M., Folini, M., & Zaffaroni, N. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm047 · Cited by 229
Expression and Genetic Analysis of XIAP-Associated Factor 1 (XAF1) in Cancer Cell Lines
Fong, W. G., Liston, P., Rajcan-Separovic, E., St. Jean, M., Craig, C., & Korneluk, R. G. (2000) · Genomics · doi:10.1006/geno.2000.6364 · Cited by 213
Cytokine-regulated expression of survivinin myeloid leukemia
Carter, B. Z., Milella, M., Altieri, D. C., & Andreeff, M. (2001) · Blood · doi:10.1182/blood.v97.9.2784 · Cited by 197
Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., Sato, M., & Sato, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0491 · Cited by 195
Suzuki, A., Hayashida, M., Ito, T., Kawano, H., Nakano, T., Miura, M., Akahane, K., & Shiraki, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203665 · Cited by 192
Human Ovarian Cancer and Cisplatin Resistance: Possible Role of Inhibitor of Apoptosis Proteins1
Li, J., Feng, Q., Kim, J.-M., Schneiderman, D., Liston, P., Li, M., Vanderhyden, B., Faught, W., Fung, M. F. K., Senterman, M., et al. (2001) · Endocrinology · doi:10.1210/endo.142.1.7897 · Cited by 185
Survivin as a Preferential Target for Cancer Therapy
Mobahat, M., Narendran, A., & Riabowol, K. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022494 · Cited by 184
Regulation of survivin expression by IGF-1/mTOR signaling
Vaira, V, Lee, C. W., Goel, H. L., Bosari, S., Languino, L. R., & Altieri, D. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210094 · Cited by 182
Liu, T., Brouha, B., & Grossman, D. (2004) · Oncogene · doi:10.1038/sj.onc.1206978 · Cited by 177
Inhibitors of Apoptotic Proteins: New Targets for Anticancer Therapy
Saleem, M., Qadir, M. I., Perveen, N., Ahmad, B., Saleem, U., Irshad, T., & Ahmad, B. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12176 · Cited by 155
Fernandez, J. G., Rodríguez, D. A., Valenzuela, M., Calderón, C. C., Urzúa, U., Munroe, D. J., Rosas, C., David Lemus, A., Díaz‐Valdivia, N., Wright, M. C., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-209 · Cited by 152
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities
Zhang, C., & Zhang, F. (2014) · Protein & Cell · doi:10.1007/s13238-014-0119-z · Cited by 149
Self-citationMüller, G. A., & Engeland, K. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07508.x · Cited by 130
KIAP, a Novel Member of the Inhibitor of Apoptosis Protein Family
Lin, J.-H., Deng, G., Huang, Q., & Morser, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4027 · Cited by 121
Chandele, A., Prasad, V., Jagtap, J. C., Shukla, R., & Shastry, P. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80051-4 · Cited by 116
Molecular Dependence of Estrogen Receptor–Negative Breast Cancer on a Notch-Survivin Signaling Axis
Lee, C. W., Raskett, C. M., Prudovsky, I. A., & Altieri, D. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6673 · Cited by 115
Carter, B. Z., Mak, D. H. F., Schober, W. D., Cabreira-Hansen, M. D. G., Beran, M., McQueen, T. J., Chen, W., & Andreeff, M. (2005) · Blood · doi:10.1182/blood-2004-12-4704 · Cited by 106
Beardmore, V. A., Ahonen, L. J., Gorbsky, G. J., & Kallio, M. J. (2004) · Journal of Cell Science · doi:10.1242/jcs.01242 · Cited by 101
Tang, C., Lu, Y.-H., Xie, J., Wang, F., Zou, J.-N., Yang, J.-S., Xing, Y., & Xi, T. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328327d476 · Cited by 97
Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity
Wang, H., Holloway, M. P., Ma, L., Cooper, Z. A., Riolo, M., Samkari, A., Elenitoba‐Johnson, K. S. J., Chin, Y. E., & Altura, R. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152777 · Cited by 97
MicroRNA regulation and therapeutic targeting of survivin in cancer.
Huang, J., Lyu, H., Wang, J., & Liu, B. (2015) · Europe PMC (PubMed Central) · Cited by 87
Survivin regulates the p53 tumor suppressor gene family
Wang, Z., Fukuda, S., & Pelus, L. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207992 · Cited by 87
The Multifunctions of WD40 Proteins in Genome Integrity and Cell Cycle Progression
Zhang, C., & Zhang, F. (2015) · Journal of Genomics · doi:10.7150/jgen.11015 · Cited by 81
Self-citationCullin Family Proteins and Tumorigenesis: Genetic Association and Molecular Mechanisms
Chen, Z., Sui, J., Zhang, F., & Zhang, C. (2015) · Journal of Cancer · doi:10.7150/jca.11076 · Cited by 80
Self-citationRb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression
Yang, J., Song, K. W., Krebs, T. L., Jackson, M. W., & Danielpour, D. (2008) · Oncogene · doi:10.1038/onc.2008.165 · Cited by 76
Effect of hypoxia-inducible factor-1α on transcription of survivin in non-small cell lung cancer
Chen, Y., Zhao, C., & Li, W. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-29 · Cited by 73
Survivin-specific T cell receptor targets tumor but not T cells
Arber, C., Feng, X., Abhyankar, H. A., Romero, E., Wu, M., Heslop, H. E., Barth, P., Dotti, G., & Savoldo, B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75876 · Cited by 72
Sehara, Y., Sawicka, K., Hwang, J.-Y., Latuszek-Barrantes, A., Etgen, A. M., & Zukin, R. S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1852-13.2013 · Cited by 66
Overexpression of survivin initiates hematologic malignancies in vivo
Small, S. H., Keerthivasan, G., Huang, Z., Gurbuxani, S. K., & Crispino, J. D. (2010) · Leukemia · doi:10.1038/leu.2010.198 · Cited by 64
Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
Yamaki, H., Nakajima, M., Shimotohno, K., & Tanaka, N. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.60 · Cited by 55
Brady, S. W., Zhang, J., Tsai, M.-H., & Yu, D. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1002693 · Cited by 54
Anandharaj, A., Cinghu, S., & Park, W. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr012 · Cited by 54
SUN, L., Peng, Q., Qu, L., Gong, L., & Jin, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3007 · Cited by 49
Singh, M. P., Chaudhry, P., Fabi, F., & Asselin, É. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-233 · Cited by 48
Lesniak (2009) · International Journal of Oncology · doi:10.3892/ijo_00000199 · Cited by 46
Caspases: Therapeutic Targets in Neurologic Disease
Troy, C. M., & Jean, Y. Y. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0307-9 · Cited by 45
Wang, H., Gambosova, K., Cooper, Z. A., Holloway, M. P., Kassai, A., Izquierdo, D., Cleveland, K., Boney, C. M., & Altura, R. A. (2010) · BMC Molecular Biology · doi:10.1186/1471-2199-11-66 · Cited by 45
Wright, M. E., Han, D. K. M., & Hockenbery, D. M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01962-1 · Cited by 43
Targeting cancer with sesterterpenoids: the new potential antitumor drugs
Zhang, C., & Liu, Y. (2015) · Journal of Natural Medicines · doi:10.1007/s11418-015-0911-y · Cited by 42
Self-citationFunction of the p53 gene: choice between life and death.
Chumakov, P. M. (2000) · PubMed · Cited by 41
NF-κB mediates aberrant activation of HIF-1 in malignant lymphoma
Qiao, Q., Nozaki, Y., Sakoe, K., Komatsu, N., & Kirito, K. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.08.007 · Cited by 41
Zhang, L., Yan, R., Zhang, Q., Wang, H., Kang, X., Li, J., Yang, S., Zhang, J., LIU, Z., & Yang, X. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1456 · Cited by 40
EGFR Signaling Promotes β-Cell Proliferation and Survivin Expression during Pregnancy
Hakonen, E. T., Ustinov, J., Palgi, J., Miettinen, P. J., & Otonkoski, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093651 · Cited by 38
Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition
Zhang, C., Liu, G., & Huang, M. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1302-6 · Cited by 37
Self-citationCritical Role of a Survivin/TGF-β/mTORC1 Axis in IGF-I-Mediated Growth of Prostate Epithelial Cells
Song, K. W., Shankar, E., Yang, J., Bane, K. L., Wahdan-Alaswad, R. S., & Danielpour, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061896 · Cited by 36
Kusner, L. L., Ciesielski, M. J., Marx, A., Kaminski, H. J., & Fenstermaker, R. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102231 · Cited by 35
Hypoxia inducible factor‐1α‐mediated activation of survivin in cervical cancer cells
Bai, H., Ge, S., Lu, J., Qian, G., & Xu, R. (2012) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.01995.x · Cited by 32
HIF-1-alpha and survivin involved in the anti-apoptotic effect of 2ME2 after global ischemia in rats
Li, Y., Xia, Z., & Chen, L.-B. (2011) · Neurological Research · doi:10.1179/1743132810y.0000000013 · Cited by 25
Survivin deficiency induces apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells
Dai, D. (2011) · Oncology Reports · doi:10.3892/or.2011.1544 · Cited by 24
Inhibition of Survivin Reduces HIF-1α, TGF-β1 and TFE3 in Salivary Adenoid Cystic Carcinoma
Wang, Y., Ma, S., Wang, W., Huang, C., Zhao, Z., Liu, B., Zhang, W., Zhao, Y., Zhang, L., & Sun, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114051 · Cited by 21
Self-citationManipulating the apoptotic pathway: potential therapeutics for cancer patients
Bates, D. J. P., & Lewis, L. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12193 · Cited by 11
Cited by
Low temperature photothermal therapy: Advances and perspectives
Yang, K., Zhao, S., Li, B., Wang, B., Lan, M., & Song, X. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214330 · Cited by 309
Nasrollahzadeh, A., Momeny, M., Fasehee, H., Yaghmaie, M., Bashash, D., Hassani, S., Mousavi, S. A., & Ghaffari, S. H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119087 · Cited by 20
Metadata
- Authors
- Chen, X., Duan, N., Zhang, C., & Zhang, W.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2016
- Volume
- 7
- Issue
- 3
- Pages
- 314-323
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W2275101974
- Cited by
- 347
- References
- 92
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.